



## Enanta Pharmaceuticals to Participate at Jefferies Global Healthcare Conference

May 31, 2023

WATERTOWN, Mass.--(BUSINESS WIRE)--May 31, 2023-- [Enanta Pharmaceuticals, Inc.](https://www.enanta.com) (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at Jefferies Global Healthcare Conference on June 7, 2023 at 12:30 p.m. ET in New York, NY.

A live webcast of the event will be accessible by visiting the "Events and Presentations" section on the "Investors" page of Enanta's website at [www.enanta.com](https://www.enanta.com). A replay of the webcast will be available following the presentation and will be archived for at least 30 days.

### About Enanta Pharmaceuticals, Inc.

Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections. Enanta's research and development programs include clinical candidates for the following disease targets: respiratory syncytial virus (RSV), SARS-CoV-2 (COVID-19) and hepatitis B virus (HBV). Enanta is also conducting research on a single agent targeting both RSV and human metapneumovirus (hMPV).

Enanta receives royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie. Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic HCV infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). Please visit [www.enanta.com](https://www.enanta.com) for more information.

View source version on [businesswire.com](https://www.businesswire.com): <https://www.businesswire.com/news/home/20230531005208/en/>

### Media and Investors

Jennifer Viera  
617-744-3848  
[jviera@enanta.com](mailto:jviera@enanta.com)

Source: Enanta Pharmaceuticals, Inc.